PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED COMPOSITION CONTAINING GLUCOKINASE ACTIVATOR AND BIGUANIDE HYPOGLYCEMIC DRUG, AS WELL AS THEIR PREPARATION METHOD, AND THEIR USE Russian patent published in 2022 - IPC A61K31/4155 A61K31/437 A61K31/497 A61P3/10 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to a hypoglycemic pharmaceutical combination, a hypoglycemic combined composition with a fixed dose, containing (a) a glucokinase activator, which is a compound HMS5552, (b) a biguanide hypoglycemic drug, which is metformin or its pharmaceutically acceptable salt, where the mass ratio of the glucokinase activator to the biguanide hypoglycemic drug is from 1:50 to 1:1, the glucokinase activator is present at a dose ranging from 1 mg to 200 mg, the biguanide hypoglycemic drug is present at a dose ranging from 100 mg to 1500 mg, a hypoglycemic pharmaceutical composition, and a hypoglycemic combined composition with a fixed dose, containing such a combination, their use in the manufacture of a drug for the prevention, slowing the progression, delay, or treatment of one or several metabolic disorders selected from a group consisting of diabetes type I, diabetes type II, impaired glucose tolerance, fasting blood glucose disorders, hyperglycemia, hyperglycemia after meals, overweight, obesity, hypertension, insulin resistance, and/or metabolic syndrome; or improvement of blood glucose control and/or lowering fasting plasma glucose, plasma glucose after meals, and/or glycosylated hemoglobin HbA1c, as well as a method for the prevention, slowing progression, delay or treatment of one or several of these metabolic disorders.

EFFECT: excellent hypoglycemic effect observed when combining HMS5552 and a biguanide hypoglycemic drug.

86 cl, 3 dwg, 3 tbl, 15 ex